In our previous findings, in the same study setting, Mygatt and colleagues10 observed no difference between tumor location and BCR‐free survival or race.10 Key differences in this study was exclusive focus on the NCCN‐defined low‐risk cohort and updated assignment of tumor location, reviewed by multiple pathologists (IS, AB, GW, WG), expanded through 2008, with both race and tumor location examined concurrently in one multivariable model. The gene discussed is BCR; the disease is neoplasm.